Applied Genetic Technologies Corporation
AGTC · NASDAQ
9/30/2022 | 6/30/2022 | 3/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | -0.02 | 0.04 | -0.15 |
| FCF Yield | -143.66% | -55.14% | -30.41% | -1.01% |
| EV / EBITDA | 0.11 | -0.62 | -0.26 | -1.68 |
| Quality | ||||
| ROIC | -104.96% | -35.29% | -19.90% | -25.89% |
| Gross Margin | 0.00% | 100.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.94 | 0.99 | 0.98 | – |
| Growth | ||||
| Revenue 3-Year CAGR | -49.02% | -49.02% | -44.08% | -72.55% |
| Free Cash Flow Growth | 8.10% | -34.64% | -1,629.48% | 95.04% |
| Safety | ||||
| Net Debt / EBITDA | 0.81 | 1.38 | 3.27 | 2.74 |
| Interest Coverage | 0.71 | -26.73 | -20.43 | 29.36 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |